Skip to main content
Premium Trial:

Request an Annual Quote

HGS Sends New Genomics-Derived Drug To Clinical Testing

Premium

ROCKVILLE, Md.--Human Genome Sciences here has announced what it claims is the first genomics-derived drug to enter clinical testing. The company filed an Investigational New Drug (IND) application last month and will soon begin enrolling patients in a Phase I study of a human protein that may improve chemotherapy treatments.

"We believe MPIF-1 is a dual first for HGSI, the first genomics-derived therapeutic product candidate to enter clinical trials and our first IND. We expect that there will be many more IND's to follow, from Human Genome Sciences and others," commented William Haseltine, the company's chairman and CEO. The company called MPIF-1 "the tip of a very large iceberg" of Human Genome Sciences' potential therapeutic products based on genome technology.

Filed under

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.